Safety of Advanced Combination Treatment With Selective JAK1 Inhibitors and Biological Therapies in Inflammatory Bowel Diseases: A Real World Experience
Alimentary Pharmacology & Therapeutics · 2025
DOI: 10.1111/apt.70077 ↗At a glance
Multizentrische Studie in Alimentary Pharmacology & Therapeutics, 2025. Written by Cécile Cussac and 7 co-authors. Institution: Department of Gastroenterology and Pancreatology, Hôpital Rangueil, CHU de Toulouse, Université Toulouse Paul Sabatier, Toulouse, France. Major MEDLINE topics: Inflammatory Bowel Diseases, Janus Kinase 1, Janus Kinase Inhibitors. Cited 1 times so far (Crossref); 10 references. The full text is freely available (open access, CC BY-NC-ND 4.0).
Abstract (original language)
This multicenter retrospective study examines 18 patients with difficult‐to‐treat inflammatory bowel diseases who received advanced combination treatment (ACT) with selective JAK1 inhibitors and biologics, totaling 11.8 patient‐years of exposure. Treatment was discontinued in three patients due to adverse events. At 3 months, 77.8% achieved steroid‐free clinical remission. The infection incidence rate was 25.4 per 100 person‐years (95% CI: 6.47–69.19), though the wide confidence interval limits conclusions on safety differences with monotherapy. These findings highlight the importance of preventive measures, careful patient selection, and rigorous monitoring to mitigate infection risks associated with ACT.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Gastroenterology and Pancreatology, Hôpital Rangueil, CHU de Toulouse, Université Toulouse Paul Sabatier, Toulouse, France.
- Department of Gastroenterology and Hepatology, Centre Médico-Chirurgical Magellan, Hôpital Haut-Lévêque, CHU de Bordeaux, Bordeaux, France.
- Université de Bordeaux; INSERM CIC 1401, Bordeaux, France.
- Department of Hepato-Gastroenterology, Hôpital Saint-Eloi, CHU Montpellier, Université de Montpellier, Montpellier, France.
- Department of Gastroenterology, Nimes University Hospital, Nimes, France.
ORCID profiles: Pauline Rivière, Romain Altwegg, David Laharie
Cite
APA
Cussac, C., Rivière, P., Altwegg, R., Caillo, L., Poullenot, F., Laharie, D., Gilletta, C., & Le Cosquer, G. (2025). Safety of Advanced Combination Treatment With Selective JAK1 Inhibitors and Biological Therapies in Inflammatory Bowel Diseases: A Real World Experience. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.70077
Vancouver
Cussac C, Rivière P, Altwegg R, Caillo L, Poullenot F, Laharie D, et al. Safety of Advanced Combination Treatment With Selective JAK1 Inhibitors and Biological Therapies in Inflammatory Bowel Diseases: A Real World Experience. Alimentary Pharmacology & Therapeutics. 2025. doi:10.1111/apt.70077
BibTeX
@article{Cussac2025,
author = {Cussac, Cécile and Rivière, Pauline and Altwegg, Romain and Caillo, Ludovic and Poullenot, Florian and Laharie, David and Gilletta, Cyrielle and Le Cosquer, Guillaume},
title = {Safety of Advanced Combination Treatment With Selective JAK1 Inhibitors and Biological Therapies in Inflammatory Bowel Diseases: A Real World Experience},
journal = {Alimentary Pharmacology & Therapeutics},
year = {2025},
doi = {10.1111/apt.70077}
}
EUVIMED